PURPOSE: To investigate and clarify the relationship between circulating 25-hydroxyvitamin D level and prostate cancer risk. METHODS: We conducted the meta-analysis to better evaluate the association. Terms "25-Hydroxyvitamin D"/"vitamin D" and "prostate cancer" were used for literature search. RESULTS: We identified 21 relevant publications from databases of PubMed and MEDLINE and included 11,941 cases and 13,870 controls in the meta-analysis. Overall studies revealed a significant 17 % elevated risk of prostate cancer for individuals with higher level of 25-hydroxyvitamin D (OR = 1.17, 95 % CI = 1.05-1.30, P = 0.004), and no publication bias was found in the calculations (P = 0.629). Subgroup analysis confirmed the association from nested case-control study group, studies from USA group and studies using serum samples group (nested case-control studies: OR = 1.17, 95 % CI = 1.08-1.27, P < 0.001; USA: OR = 1.15, 95 % CI = 1.03-1.29, P = 0.017; serum: OR = 1.20, 95 % CI = 1.01-1.42, P = 0.042); moreover, sensitivity tests also indicated significant results in studies from Europe and studies conducting with plasma samples after exclusion of some influential single study from the analysis, respectively (Europe: OR = 1.21, 95 % CI = 1.04-1.40, P = 0.014; plasma: OR = 1.13, 95 % CI = 1.00-1.27, P = 0.05). CONCLUSIONS: Our meta-analysis, for the first time, suggested significant positive relationship between high level of 25-hydroxyvitamin D and increased risk of prostate cancer, reminding us that more concern should be taken into account during assessing the effect of 25-hydroxyvitamin D.
PURPOSE: To investigate and clarify the relationship between circulating 25-hydroxyvitamin D level and prostate cancer risk. METHODS: We conducted the meta-analysis to better evaluate the association. Terms "25-Hydroxyvitamin D"/"vitamin D" and "prostate cancer" were used for literature search. RESULTS: We identified 21 relevant publications from databases of PubMed and MEDLINE and included 11,941 cases and 13,870 controls in the meta-analysis. Overall studies revealed a significant 17 % elevated risk of prostate cancer for individuals with higher level of 25-hydroxyvitamin D (OR = 1.17, 95 % CI = 1.05-1.30, P = 0.004), and no publication bias was found in the calculations (P = 0.629). Subgroup analysis confirmed the association from nested case-control study group, studies from USA group and studies using serum samples group (nested case-control studies: OR = 1.17, 95 % CI = 1.08-1.27, P < 0.001; USA: OR = 1.15, 95 % CI = 1.03-1.29, P = 0.017; serum: OR = 1.20, 95 % CI = 1.01-1.42, P = 0.042); moreover, sensitivity tests also indicated significant results in studies from Europe and studies conducting with plasma samples after exclusion of some influential single study from the analysis, respectively (Europe: OR = 1.21, 95 % CI = 1.04-1.40, P = 0.014; plasma: OR = 1.13, 95 % CI = 1.00-1.27, P = 0.05). CONCLUSIONS: Our meta-analysis, for the first time, suggested significant positive relationship between high level of 25-hydroxyvitamin D and increased risk of prostate cancer, reminding us that more concern should be taken into account during assessing the effect of 25-hydroxyvitamin D.
Authors: Panagiota N Mitrou; Demetrius Albanes; Stephanie J Weinstein; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Michael F Leitzmann Journal: Int J Cancer Date: 2007-06-01 Impact factor: 7.396
Authors: Sharif B Mohr; Edward D Gorham; John E Alcaraz; Christopher J Kane; Caroline A Macera; J Kellogg Parsons; Deborah L Wingard; Cedric F Garland Journal: Anticancer Res Date: 2011-09 Impact factor: 2.480
Authors: José M Ordóñez-Mena; Ben Schöttker; Ulrike Haug; Heiko Müller; Josef Köhrle; Lutz Schomburg; Bernd Holleczek; Hermann Brenner Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Christine M Barnett; Carrie M Nielson; Jackie Shannon; June M Chan; James M Shikany; Douglas C Bauer; Andrew R Hoffman; Elizabeth Barrett-Connor; Eric Orwoll; Tomasz M Beer Journal: Cancer Causes Control Date: 2010-04-10 Impact factor: 2.506
Authors: Stephanie J Weinstein; Alison M Mondul; Kai Yu; Tracy M Layne; Christian C Abnet; Neal D Freedman; Racheal Z Stolzenberg-Solomon; Unhee Lim; Mitchell H Gail; Demetrius Albanes Journal: Eur J Epidemiol Date: 2018-08-02 Impact factor: 8.082
Authors: Kathleen Torkko; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Jeannette M Schenk; M Scott Lucia; Ulrike Peters; Adrie van Bokhoven; Ian M Thompson; Marian L Neuhouser Journal: Cancer Prev Res (Phila) Date: 2020-02-26
Authors: Tracy M Layne; Stephanie J Weinstein; Barry I Graubard; Xiaomei Ma; Susan T Mayne; Demetrius Albanes Journal: Cancer Date: 2017-04-03 Impact factor: 6.860
Authors: Shakira M Nelson; Orestis A Panagiotou; Gabriella M Anic; Alison M Mondul; Satu Männistö; Stephanie J Weinstein; Demetrius Albanes Journal: Int J Epidemiol Date: 2016-08-14 Impact factor: 7.196
Authors: Gabriella M Anic; Demetrius Albanes; Sabine Rohrmann; Norma Kanarek; William G Nelson; Gary Bradwin; Nader Rifai; Katherine A McGlynn; Elizabeth A Platz; Alison M Mondul Journal: Clin Endocrinol (Oxf) Date: 2016-04-06 Impact factor: 3.478